Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects

Deborah Plana; Geoffrey Fell; Brian M. Alexander; Adam C. Palmer; Peter K. Sorger

doi:10.1038/s41467-022-28410-9

Nature Communications (Feb 2022)

Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects

Deborah Plana,
Geoffrey Fell,
Brian M. Alexander,
Adam C. Palmer,
Peter K. Sorger

Affiliations

Deborah Plana: Laboratory of Systems Pharmacology and the Department of Systems Biology, Harvard Medical School
Geoffrey Fell: Dana-Farber Cancer Institute
Brian M. Alexander: Dana-Farber Cancer Institute
Adam C. Palmer: Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Peter K. Sorger: Laboratory of Systems Pharmacology and the Department of Systems Biology, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-022-28410-9
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Analysis of more than 150 Phase 3 oncology clinical trials supports parametric statistical analysis, significantly increasing the precision of small early-phase trials and relating deviations from the Cox proportional hazards model to trial duration.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal